Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Medical hyperspectral imaging to facilitate residual tumor identification during surgery.

Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Abstract Text:

    svetlana v panasyukSvetlana V Panasyuk,shi yangShi Yang,douglas v fallerDouglas V Faller,duyen ngoDuyen Ngo,robert a lewRobert A Lew,jenny e freemanJenny E Freeman,adrianne e rogersAdrianne E Rogers,

    INTRODUCTION: Adequate evaluation of breast tumor resection at surgery continues to be an important issue in surgical care, as over 30% of postoperative tumors recur locally unless radiation is used to destroy remaining tumor cells in the field. Medical Hyperspectral Imaging (MHSI) delivers near-real time images of biomarkers in tissue, providing an assessment of pathophysiology and the potential to distinguish different tissues based on spectral characteristics. METHODS: We have used an experimental DMBA-induced rat breast tumor model to examine the intraoperative utility of MHSI, in distinguishing tumor from normal breast and other tissues. Rats bearing tumors underwent surgical exposure and MHSI imaging, followed by partial resection of the tumors, then MHSI imaging of the resection bed, and finally total resection of tumors and of grossly normal-appearing glands. Resected tissue underwent gross examination, MHSI imaging, and histopathological evaluation. RESULTS: An algorithm based on spectral characteristics of tissue types was developed to distinguish between tumor and normal tissues. Tissues including tumor, blood vessels, muscle, and connective tissue were clearly identified and differentiated by MHSI. Fragments of residual tumor 0.5-1 mm in size intentionally left in the operative bed were readily identified. MHSI demonstrated a sensitivity of 89% and a specificity of 94% for detection of residual tumor, comparable to that of histopathological examination of the tumor bed (85% and 92%, respectively). CONCLUSION: We conclude that MHSI may be useful in identifying small residual tumor in a tumor resection bed and for indicating areas requiring more extensive resection and more effective biopsy locations to the surgeon.

    Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Publishing Authors By Initials

    sv panasyukSV Panasyuk,s yangS Yang,dv fallerDV Faller,d ngoD Ngo,ra lewRA Lew,je freemanJE Freeman,ae rogersAE Rogers,

    For similar investigative techniques: chemistry, analytical: photometry: spectrophotometry: spectrophotometry, infrared research abstracts see: investigative techniques: chemistry, analytical: photometry: spectrophotometry: spectrophotometry, infrared research

    PUBMED ID PMID:

    MEDLINE DATE:

    Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: Cancer biology & therapy

    VOLUME: 6

    Page Numbers: 439-46

    Journal Abbreviation:

    ISSN: 1538-4047

    DAY: 16

    MONTH: 03

    YEAR: 2007

    Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 101137842

    Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Keywords Mesh Terms:

    KEYWORDS: Spectrophotometry, Infrared

    MESH TERMS: instrumentation

    Chemical & Substance for Abstract: Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Information

    Substance Name: 9,10-Dimethyl-1,2-benzanthracene

    Registry Number: 57-97-6

    Grant and Affiliation Information for Medical hyperspectral imaging to facilitate residual tumor identification during surgery.

    AFFILIATION: HyperMed, Inc., Waltham, Massachusetts, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NHLBI

    GRANT: T32-HL07501

    ACRONYM: HL

    MEDLINETA: Cancer Biol Ther

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Medical hyperspectral imaging to facilitate residual tumor identification during surgery Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News